Supplementary_Section_30Oct2018 – Supplemental material for Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study

Bessette, Louis; Haraoui, Boulos; Chow, Andrew; Fortin, Isabelle; Dixit, Sanjay; Khraishi, Majed; Haaland, Derek; Elmoufti, Sami; Staelens, Fabienne; Bogatyreva, Irina; Syrotuik, Jerry; Shaikh, Saeed

doi:10.25384/SAGE.7808048.v1

Supplementary_Section_30Oct2018.docx (1018.27 kB)

Supplementary_Section_30Oct2018 – Supplemental material for Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study

journal contribution

posted on 2019-03-05, 12:00 authored by Louis Bessette, Boulos Haraoui, Andrew Chow, Isabelle Fortin, Sanjay Dixit, Majed Khraishi, Derek Haaland, Sami Elmoufti, Fabienne Staelens, Irina Bogatyreva, Jerry Syrotuik, Saeed Shaikh

Supplemental material, Supplementary_Section_30Oct2018 for Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study by Louis Bessette, Boulos Haraoui, Andrew Chow, Isabelle Fortin, Sanjay Dixit, Majed Khraishi, Derek Haaland, Sami Elmoufti, Fabienne Staelens, Irina Bogatyreva, Jerry Syrotuik and Saeed Shaikh in Therapeutic Advances in Musculoskeletal Disease